Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial
Work
Year: 2022
Type: article
Abstract: To investigate efficacy and safety of trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2 (HER2)-low gastric or gastroesophageal junction (GEJ) adenocarcinoma.Patients with loca... more
Source: Journal of Clinical Oncology
Institutions The Cancer Institute Hospital, Seoul National University, National Cancer Center Hospital East, Osaka International Cancer Institute, Asan Medical Center +10 more
Cites: 21
Cited by: 78
Related to: 10
FWCI: 15.79
Citation percentile (by year/subfield): 84.33
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: hybrid